Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | HTR7 | P34969 | 5/20 | 0.68 |
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MC4R | P32245 | 1/20 | 0.59 |
| ▸ | CCR3 | P51677 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27550580 | 0.89 | KMT2A (0.69) | KMT2AHTR7HTR1ASIGMAR1ALDH1A1 | |
| SCHEMBL8189169 | 0.86 | KMT2A (0.66) | KMT2AHTR7HTR1ASIGMAR1ALDH1A1 | |
| SCHEMBL22639905 | 0.86 | SIGMAR1 (0.61) | KMT2AHTR7HTR1ASIGMAR1ALDH1A1 | |
| SCHEMBL10902220 | 0.85 | ADRA1D (0.62) | KMT2AHTR7HTR1ASIGMAR1TSHR | |
| SCHEMBL5373264 | 0.85 | ALDH1A1 (0.67) | KMT2AHTR7HTR1AALDH1A1 | |
| SCHEMBL4512612 | 0.85 | ALDH1A1 (0.71) | KMT2AHTR7HTR1ASIGMAR1ALDH1A1 | |
| SCHEMBL18118445 | 0.85 | SCN5A (0.60) | KMT2AHTR7HTR1AALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL3844581 | 0.83 | ALDH1A1 (0.69) | KMT2AHTR7HTR1ASIGMAR1ALDH1A1 | |
| SCHEMBL12150889 | 0.83 | KMT2A (0.76) | KMT2AHTR7HTR1AALDH1A1TSHR | |
| SCHEMBL3040556 | 0.83 | HRH3 (0.71) | KMT2AALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1191028-B1 | TRICYCLIC COMPOUNDS HAVING SPIRO UNION | MOCHIDA PHARM CO LTD (JP) | 2004-11-03 | — | — | EP | claimed |
| EP-1191028-A1 | TRICYCLIC COMPOUNDS HAVING SPIRO UNION | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-27 | — | — | EP | claimed |
| EP-2388003-B1 | Colchicine derivatives | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3207929-B1 | COLCHICINE DERIVATIVES FOR THE TREATMENT OF CANCER | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3207929-A2 | COLCHICINE DERIVATIVES | California Pacific Medical Center (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9587035-B2 | Assay for benzylpiperazine and metabolites | RANDOX LABORATORIES LIMITED (GB) | 2017-03-07 | — | — | US | disclosed |
| EP-1617843-B1 | COLCHICINE DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-1643987-B1 | PODOPHYLLOTOXIN DERIVATIVES | CALIFORNIA PACIFIC MED CENTER (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-2679241-B1 | Assay for benzylpiperazines and metabolites | RANDOX LAB LTD (GB) | 2016-09-14 | — | — | EP | disclosed |
| US-8158809-B2 | Podophyllotoxin derivatives | SUTTER WEST BAY HOSPITALS (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2388003-A2 | Colchicine derivatives | California Pacific Medical Center (US) | 2011-11-23 | — | — | EP | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1308513-A1 | USE OF POLYPEPTIDE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-20030073698-A1 | Nitrogen-based camptothecin derivatives | US ARMY, SECRETARY OF THE ARMY | 2003-04-17 | — | — | US | disclosed |
| US-20030032624-A1 | Nitrogen-based camptothecin derivatives | US ARMY, SECRETARY OF THE ARMY | 2003-02-13 | — | — | US | disclosed |
| WO-2002070525-A2 | NITROGEN-BASED CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2002-09-12 | — | — | WO | disclosed |
| US-6403604-B1 | ANTITUMOR | CALIFORNIA PACIFIC MEDICAL CENTER | 2002-06-11 | — | — | US | disclosed |
| EP-0711768-B1 | BENZIMIDAZOLE DERIVATIVE | MITSUI CHEMICALS INC (JP) | 2002-02-13 | — | — | EP | disclosed |
| US-5852011-A | Benzimidazole derivatives | MITSUI CHEMICALS, INC. (JP) | 1998-12-22 | — | — | US | disclosed |
| EP-0711768-A1 | BENZIMIDAZOLE DERIVATIVE | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073698-A1 | Nitrogen-based camptothecin derivatives | DCK, NEK11, NME1 | KMT2A 2819/4885HTR7 1517/4885HTR1A 2437/4885 |
| US-20030032624-A1 | Nitrogen-based camptothecin derivatives | DCK, NEK11, NME1 | KMT2A 2819/4885HTR7 1517/4885HTR1A 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.